ADC Therapeutics SA

Ms. Pope has more than 30 years of experience in Human Resources, with over 20 years in the pharmaceutical industry. Most recently, Ms. Pope was the SVP of Human Resources at Array BioPharma where she helped to build and transform the organization in preparation for the first commercial product launch. Prior to her role at […]

Mr. Graham serves as Chief Legal Officer and has over 25 years of legal, compliance and executive management experience in publicly and privately held pharmaceutical and medical device companies. Most recently, from 2015 until its sale to Halozyme Therapeutics, Inc. in 2022, Mr. Graham served as Executive Vice President, General Counsel, Chief Compliance Officer, Human […]

David Ege is the Chief Technical Officer of ADCT. He has more than 20 years of experience in the pharmaceutical industry, with a focus in biologics, vaccines and novel modalities. Prior to joining ADCT Dr. Ege was CTO, head of Process Development, Quality and Supply at Seres Therapeutics since 2020. He began his career at […]

Victor Sandor, MD, is a Non-Executive Director on the Board of Directors of ADC Therapeutics. Dr. Sandor was most recently Chief Medical Officer at Array BioPharma, Inc. prior to its acquisition by Pfizer Inc. At Array, Dr. Sandor was instrumental in obtaining the approval of Braftovi® (encorafenib) and Mektovi® (binimetinib). Prior to joining Array, he […]

Tyrell J. Rivers, PhD, has served as a member of the Board of Directors of ADC Therapeutics since June 2018. Dr. Rivers is also a Vice President of Corporate Ventures within AstraZeneca’s Corporate Development group, having responsibility for equity investments, mergers and acquisitions, and divestments. Prior to this role, Dr. Rivers was at MedImmune Ventures, […]

Ms. Harrington-Smith joined ADC Therapeutics in November 2022 with over 20 years of experience in the pharmaceutical industry. Most recently, she served as Chief Commercial Officer at ImmunoGen. Prior to joining ImmunoGen, Ms. Harrington-Smith held roles of increasing responsibility at Novartis Pharmaceuticals including US Commercial Head of Hematology, where she led the commercial teams responsible […]

Mohamed Zaki, MD, PhD joined ADC Therapeutics in January 2023 bringing over 20 years of global biopharmaceutical experience in hematology and oncology drug development. Dr. Zaki joined ADC Therapeutics from Abbvie where he spent the last four years, most recently as Vice President and Global Head of Oncology Development. Prior to Abbvie, he spent nine […]

Viviane Monges is a Non-Executive Director on the Board of Directors of ADC Therapeutics. Ms. Monges has more than 30 years of executive-level financial leadership experience with global corporations, predominantly in the pharmaceutical industry. From 2015 to 2017, she served as Chief Financial Officer (CFO) of the Business Excellence Division at Nestlé, S.A. Prior to […]

Jose “Pepe” Carmona joined ADC Therapeutics as Chief Financial Officer in December 2022 bringing over 20 years of financial experience in the biotechnology and pharmaceutical industries. Prior to ADC Therapeutics, Mr. Carmona was the CFO at Rubius Therapeutics, a biopharmaceutical company engineering red blood cells to create a new class of cellular medicines for cancer […]

Ameet Mallik joined ADC Therapeutics in May 2022 and has over 25 years of industry experience. Before joining ADC Therapeutics, he served as CEO of Rafael Holdings, a novel cancer and immune metabolism therapeutics company. Prior to Rafael Holdings, Mr. Mallik spent more than 16 years at Novartis where he served as Executive Vice President […]